Elvitegravir, cobicistat, emtricitabine, and tenofovir (Oral)
Medically reviewed by Drugs.com. Last updated on May 29, 2022.
Posttreatment Acute Exacerbation of Hepatitis BSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine or tenofovir disoproxil fumarate, two of the components of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate tablets. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted .
Commonly used brand name(s)
In the U.S.
- Stribild
Available Dosage Forms:
- Tablet
Therapeutic Class: Anti-Infective Agent
Pharmacologic Class: Integrase Inhibitor
Uses for elvitegravir, cobicistat, emtricitabine, and tenofovir
Elvitegravir, cobicistat, emtricitabine, and tenofovir combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Elvitegravir, cobicistat, emtricitabine, and tenofovir is usually given to adult patients who have yet not received any medicine for HIV infection.
Elvitegravir, cobicistat, emtricitabine, and tenofovir combination will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Elvitegravir, cobicistat, emtricitabine, and tenofovir will not keep you from spreading HIV to other people. People who receive elvitegravir, cobicistat, emtricitabine, and tenofovir may continue to have other problems usually related to AIDS or HIV disease.
Elvitegravir, cobicistat, emtricitabine, and tenofovir is available only with your doctor's prescription.
Before using elvitegravir, cobicistat, emtricitabine, and tenofovir
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For elvitegravir, cobicistat, emtricitabine, and tenofovir, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to elvitegravir, cobicistat, emtricitabine, and tenofovir or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of elvitegravir, cobicistat, emtricitabine, and tenofovir combination in children younger than 12 years of age or weighing less than 35 kilograms. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of elvitegravir, cobicistat, emtricitabine, and tenofovir combination in the elderly. However, elderly patients are more likely to have age-related kidney, liver, or heart problems, which may require caution for patients receiving elvitegravir, cobicistat, emtricitabine, and tenofovir.
